TheEdgeResearch
Home / Stocks / NVCR

NovoCure Limited (NVCR)

NASDAQ Healthcare Medical - Instruments & Supplies
$14.28 ▼ -20.00%
Market Cap
$1.65B
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Beta
0.92
52-Wk Range
9.82-18.92
CEO
Frank Leonard
Country
US
Currency
USD

NovoCure Limited operates as an oncology enterprise specializing in the development, manufacturing, and global commercialization of its proprietary Tumor Treating Fields (TTFields) technology. These innovative devices are engineered to treat solid tumor cancers, with the company's market presence spanning the United States, Europe, the Middle East, Africa, Japan, and Greater China. The company's commercialized offerings include Optune, which is indicated for glioblastoma, and Optune Lua, approved for use in malignant pleural mesothelioma. Beyond these established treatments, NovoCure actively …

Open full interactive analysis & DCF →